SeaStar Medical’s second quarter 2026 revenue beat estimates as pediatric QUELIMMUNE sales surged 82% YoY

SeaStar Medical reported second quarter 2026 revenue of $0.6 million, exceeding analyst expectations of $0.49 million, driven by the expanding commercial adoption of its QUELIMMUNE pediatric therapy. The company achieved a narrower-than-expected net loss per share of $0.91. While top-line growth was strong, operating expenses rose significantly to $4.4 million as the company advanced its adult clinical trials and commercial infrastructure.

Key Highlights

• Net revenue increased 82% year-over-year to $0.6 million, supported by a robust 91% gross margin on QUELIMMUNE product sales.
• The company expanded its customer base to 20 top-rated children's hospitals, adding three new facilities during the second quarter.
• Enrollment for the NEUTRALIZE-AKI pivotal clinical trial in adults reached 223 of 339 target patients, with completion anticipated around year-end or early 2027.